NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy
Alexandre Bazinet1, Alessandra Ferrajoli1, Nitin Jain1
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Blood Advances
|March 25, 2026
Abstract
No abstract available in PubMed .
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.9K
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
834
